Cargando…
Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan
BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408926/ https://www.ncbi.nlm.nih.gov/pubmed/34465373 http://dx.doi.org/10.1186/s40780-021-00214-x |
_version_ | 1783746892182585344 |
---|---|
author | Saito, Jumpei Hanawa, Takehisa Matsumoto, Takahiro Yoshikawa, Nozomi Harada, Tsutomu Iwahashi, Kana Nakamura, Hidefumi Yamatani, Akimasa |
author_facet | Saito, Jumpei Hanawa, Takehisa Matsumoto, Takahiro Yoshikawa, Nozomi Harada, Tsutomu Iwahashi, Kana Nakamura, Hidefumi Yamatani, Akimasa |
author_sort | Saito, Jumpei |
collection | PubMed |
description | BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often compounded into a powder form by pharmacists to achieve dosage adjustments for administration to pediatric patients. However, the stability and quality of compounded clonidine powder have not been verified. The objectives of this study were to formulate a 0.2 mg/g oral clonidine hydrochloride powder and assess the stability and physical properties of this compounded product in storage. METHODS: A 0.2 mg/g clonidine powder was prepared by adding lactose monohydrate to crushed and filtrated clonidine tablets. The powder was stored in polycarbonate amber bottles or coated paper packages laminated with cellophane and polyethylene. The stability of clonidine at 25 °C ± 2 °C and 60% ± 5% relative humidity was examined over a 120-d period in “bottle (closed),” “bottle (in use),” and “laminated paper” storage conditions. Drug dissolution and powder X-ray diffraction analysis were conducted to assess physicochemical stabilities. Validated liquid chromatography-diode array detection was used to detect and quantify clonidine and its degradation product, 2,6-dichloroaniline (2,6-DCA). RESULTS: Clonidine content was maintained between 90.0 and 110.0% of the initial contents in all packaging and storage conditions. After 120 d of storage, 2,6-DCA was not detected, and no crystallographic and dissolution changes were observed. CONCLUSIONS: Compounded clonidine powder stability was maintained for 120 d at 25 °C ± 2 °C and 60% ± 5% relative humidity. This information may contribute to the management of clonidine compounded powder in community and hospital pharmacies in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-021-00214-x. |
format | Online Article Text |
id | pubmed-8408926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84089262021-09-01 Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan Saito, Jumpei Hanawa, Takehisa Matsumoto, Takahiro Yoshikawa, Nozomi Harada, Tsutomu Iwahashi, Kana Nakamura, Hidefumi Yamatani, Akimasa J Pharm Health Care Sci Research Article BACKGROUND: Clonidine hydrochloride is used to treat sedative agent withdrawals, malignant hypertension, and anesthesia complications. Clonidine is also prescribed off-label to pediatric patients at a dose of 1 μg/kg. The commercially available enteral form of clonidine, Catapres® tablets, is often compounded into a powder form by pharmacists to achieve dosage adjustments for administration to pediatric patients. However, the stability and quality of compounded clonidine powder have not been verified. The objectives of this study were to formulate a 0.2 mg/g oral clonidine hydrochloride powder and assess the stability and physical properties of this compounded product in storage. METHODS: A 0.2 mg/g clonidine powder was prepared by adding lactose monohydrate to crushed and filtrated clonidine tablets. The powder was stored in polycarbonate amber bottles or coated paper packages laminated with cellophane and polyethylene. The stability of clonidine at 25 °C ± 2 °C and 60% ± 5% relative humidity was examined over a 120-d period in “bottle (closed),” “bottle (in use),” and “laminated paper” storage conditions. Drug dissolution and powder X-ray diffraction analysis were conducted to assess physicochemical stabilities. Validated liquid chromatography-diode array detection was used to detect and quantify clonidine and its degradation product, 2,6-dichloroaniline (2,6-DCA). RESULTS: Clonidine content was maintained between 90.0 and 110.0% of the initial contents in all packaging and storage conditions. After 120 d of storage, 2,6-DCA was not detected, and no crystallographic and dissolution changes were observed. CONCLUSIONS: Compounded clonidine powder stability was maintained for 120 d at 25 °C ± 2 °C and 60% ± 5% relative humidity. This information may contribute to the management of clonidine compounded powder in community and hospital pharmacies in Japan. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40780-021-00214-x. BioMed Central 2021-09-01 /pmc/articles/PMC8408926/ /pubmed/34465373 http://dx.doi.org/10.1186/s40780-021-00214-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Saito, Jumpei Hanawa, Takehisa Matsumoto, Takahiro Yoshikawa, Nozomi Harada, Tsutomu Iwahashi, Kana Nakamura, Hidefumi Yamatani, Akimasa Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title | Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title_full | Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title_fullStr | Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title_full_unstemmed | Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title_short | Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan |
title_sort | stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408926/ https://www.ncbi.nlm.nih.gov/pubmed/34465373 http://dx.doi.org/10.1186/s40780-021-00214-x |
work_keys_str_mv | AT saitojumpei stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT hanawatakehisa stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT matsumototakahiro stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT yoshikawanozomi stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT haradatsutomu stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT iwahashikana stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT nakamurahidefumi stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan AT yamataniakimasa stabilityofclonidinehydrochlorideinanoralpowderformcompoundedforpediatricpatientsinjapan |